Welcome to our dedicated page for Scisparc SEC filings (Ticker: SPRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SciSparc Ltd. filings document foreign private issuer disclosures for a clinical-stage pharmaceutical company with ordinary shares listed on Nasdaq. The record includes Form 6-K reports and Form 20-F references covering NeuroThera Labs patent and clinical-regulatory updates, cannabinoid-based drug programs, the MUSE endoscopic-system IP portfolio, and hemp seed oil-based product operations.
The company’s SEC materials also describe capital-structure and financing matters, including convertible promissory notes, warrants, resale registration statements, Form F-3 and Form S-8 incorporation, shareholder meeting approvals, reverse-share-split mechanics, Nasdaq continued-listing compliance, governance matters and risk-related disclosure categories.
N2OFF, Inc. (NITO) reported an initial statement of beneficial ownership on Form 3. The filing shows the reporting person is a Director and directly holds 490,751 shares of common stock.
The event date for this ownership report is 10/20/2025. No derivative securities were listed in the submission.
SciSparc Ltd. (SPRC) closed the sale of its stake in MitoCareX to N2OFF on October 20, 2025. In exchange, SciSparc received a cash payment of $700,000 and 490,751 shares of N2OFF common stock, representing 16.75% of N2OFF on a fully diluted basis.
The transaction leaves N2OFF owning 100% of MitoCareX, while SciSparc now holds a meaningful equity position in N2OFF plus cash proceeds. The company also furnished a press release as Exhibit 99.1 detailing the closing and MitoCareX’s focus on drug discovery for resistant cancers.
SciSparc Ltd. entered into an asset and share purchase agreement to obtain a controlling interest in Miza III Ventures Inc. by transferring its pharmaceutical portfolio and approximately 50.9% of SciSparc Nutraceuticals Inc.
At closing, SciSparc will receive 63,300,000 Miza common shares at CAD 0.25 per share, 4,000,000 five‑year warrants at an exercise price of CAD 0.25, and up to 48,000,000 contingent shares upon milestones. This represents a post‑closing equity interest of 75% in Miza, or up to approximately 84% if all milestones are achieved. The transaction reflects a value of approximately CAD 4.5 million for Miza and approximately CAD 15.8 million for the transferred assets.
Miza is expected to be renamed NeuroThera Labs Inc. and operate in pharmaceutical and supplemental sectors. Completion is anticipated by October 22, 2025, subject to conditions, with no assurance of closing. Upon closing and TSXV approval, SciSparc also plans an unsecured convertible note of up to CAD 1 million at 7%, maturing in two years and convertible at CAD 0.25 per share up to 4,000,000 shares. The securities will be issued under exemptions from U.S. registration.
SciSparc Ltd. disclosed a framework agreement to merge with AutoMax Ltd. The agreement is described as dated October 6, 2025 and names SciSparc Merger Sub Ltd. as a party, indicating a planned transaction structure using a merger subsidiary. The company issued a press release titled "SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors." The filing includes an officer signature block listing Oz Adler as Chief Executive Officer and Chief Financial Officer. The disclosure conveys a strategic transaction is underway but provides only the agreement notice and the press release reference without terms, financial consideration, approvals, or closing conditions.
SciSparc Ltd. announced that N2OFF shareholders approved a merger with MitoCareX, SciSparc's majority-owned subsidiary. The press release states the transaction was approved and identifies MitoCareX as a drug discovery company focused on therapies for resistant cancers, specifically naming pancreatic cancer and non-small cell lung cancer. The filing is presented as a current report (Form 6-K) and is signed by Oz Adler as Chief Executive Officer and Chief Financial Officer on September 30, 2025. The release does not include financial terms, an effective merger date, or post-transaction ownership percentages.
SciSparc Ltd. entered into inducement letter agreements with holders of its existing warrants to purchase up to 361,548 ordinary shares. The holders agreed to exercise all of these warrants for cash at a reduced exercise price of $3.10 per share, down from $11.6172. SciSparc expects to receive approximately $1.12 million in gross proceeds from these cash exercises.
The closing of these transactions is expected on or about September 29, 2025, subject to customary closing conditions, and the company plans to use the net proceeds for working capital and general corporate purposes. The resale of the ordinary shares underlying these warrants was previously registered on an effective Form F-3 shelf registration statement.
SciSparc Ltd. disclosed the launch of an innovative quantum computing-enabled 3D protein modeling initiative intended to support AI-driven drug discovery. The report cites the program name and presents a company signature by Oz Adler as Chief Executive Officer and Chief Financial Officer on September 25, 2025. The filing attaches standard registration statement references but contains no financial results, funding details, partner names, timelines, or measurable milestones. This limits the ability to assess near-term commercial or revenue impact.
SciSparc Ltd. reports that AutoMax Motors Ltd. has obtained a court-ordered pause in the approval process for their planned merger. On September 16, 2025, AutoMax filed a motion with the Jerusalem District Court under Israeli companies law, asking to stay proceedings related to its shareholders’ approval of the merger with SciSparc and a merger subsidiary.
The Court granted the request, staying the proceedings until September 30, 2025, or until AutoMax notifies the Court that conditions precedent to completing the merger have not been met, whichever comes first. AutoMax sought this stay because recent developments in its business operations raise uncertainty about its ability to satisfy the closing conditions for the merger.
SciSparc Ltd. reports that in August 2025 certain investors converted portions of previously issued convertible debentures into equity. The debentures were originally issued in an aggregate principal amount of $4.2 million and are convertible into ordinary shares. Based on conversion notices submitted by investors, the company issued 999,528 ordinary shares upon conversion of outstanding principal and accrued interest. After these issuances, SciSparc had 1,622,273 ordinary shares issued and outstanding as of August 28, 2025, and $175,000 principal amount of debentures remained outstanding.